跳至主要内容
临床试验/EUCTR2020-003640-88-AT
EUCTR2020-003640-88-AT招募中1 期

A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with 177Lu-IPN01072 in an Ipsen-sponsored Clinical Study

Ariceum Therapeutics GmbH0 个研究点目标入组 38 人开始时间: 2021年6月15日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
38

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • (1) Participant is capable of giving signed informed consent as described in Appendix 10.1 of the protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • (2) Participant must have received at least one infusion of 177Lu-IPN01072 in Study OPS-C- 001
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 19
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 19

排除标准

  • There are no exclusion criteria in this safety surveillance study.

研究者

相似试验